Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous tocilizumab in active rheumatoid arthritis after inadequate response to non-biologic DMARDs
NL-OMON38533Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoints: Incidence and severity of adverse events, Adverse events leading to dose modification or withdrawal and 10 more. Started Jan 2014; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON38533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38533.